Hypolipidemic Agents

"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.

Descriptor ID	D000960
MeSH Number(s)	D27.505.519.186.071 D27.505.954.557.500
Concept/Terms	Hypolipidemic Agents Hypolipidemic Agents Agents, Hypolipidemic Antihyperlipidemics Hypolipidemic Drugs Drugs, Hypolipidemic Antilipemic Drugs Drugs, Antilipemic Antilipemics Antihyperlipemics Antilipemic Agents Agents, Antilipemic

Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]

Below are MeSH descriptors whose meaning is related to "Hypolipidemic Agents".

Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.

Bar chart showing 66 publications over 25 distinct years, with a maximum of 7 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	1	0	1
1994	1	0	1
1996	1	0	1
2000	1	1	2
2001	1	0	1
2002	0	4	4
2003	0	2	2
2004	1	0	1
2005	2	3	5
2006	2	3	5
2007	2	2	4
2008	1	1	2
2009	3	0	3
2010	0	1	1
2011	2	2	4
2012	0	1	1
2013	3	0	3
2014	3	2	5
2015	2	0	2
2016	1	2	3
2017	3	4	7
2018	0	2	2
2019	1	0	1
2020	2	1	3
2021	2	0	2

Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.

Wiggins BS. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia. J Cardiovasc Pharmacol. 2021 11 01; 78(5):e631-e640.

View in: PubMed
Januszewski AS, Chen D, Scott RS, O'Connell RL, Aryal NR, Sullivan DR, Watts GF, Taskinen MR, Barter PJ, Best JD, Simes RJ, Keech AC, Jenkins AJ. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Sci Rep. 2021 09 21; 11(1):18708.

View in: PubMed
Fu D, Yu JY, Connell AR, Hookham MB, McLeese RH, Lyons TJ. Effects of Modified Low-Density Lipoproteins and Fenofibrate on an Outer Blood-Retina Barrier Model: Implications for Diabetic Retinopathy. J Ocul Pharmacol Ther. 2020 12; 36(10):754-764.

View in: PubMed
Ong KL, Wu L, Januszewski AS, O'Connell RL, Xu A, Rye KA, Ma RCW, Li H, Jenkins AJ, Jia W, Keech AC. Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Res Clin Pract. 2020 Nov; 169:108450.

View in: PubMed
Cao JY, Waldman B, O'Connell R, Sullivan DR, Scott RS, Aryal N, Gebski V, Marschner I, Taskinen MR, Simes JR, McGill N, Jenkins AJ, Keech AC. Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020 08; 22(8):1388-1396.

View in: PubMed
Patti AM, Giglio RV, Papanas N, Rizzo M, Rizvi AA. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):129-143.

View in: PubMed
Torok RD, Li JS, Kannankeril PJ, Atz AM, Bishai R, Bolotin E, Breitenstein S, Chen C, Diacovo T, Feltes T, Furlong P, Hanna M, Graham EM, Hsu D, Ivy DD, Murphy D, Kammerman LA, Kearns G, Lawrence J, Lebeaut B, Li D, Male C, McCrindle B, Mugnier P, Newburger JW, Pearson GD, Peiris V, Percival L, Pina M, Portman R, Shaddy R, Stockbridge NL, Temple R, Hill KD. Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. J Am Heart Assoc. 2018 02 10; 7(4).

View in: PubMed
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.

View in: PubMed
Keech AC, Jenkins AJ. Triglyceride-lowering trials. Curr Opin Lipidol. 2017 Dec; 28(6):477-487.

View in: PubMed
Ong KL, O'Connell R, Januszewski AS, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Scott RS, Taskinen MR, Waldman B, Colman PG, Best JD, Simes JR, Rye KA, Keech AC. Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clin Chem. 2017 Jul; 63(7):1261-1270.

View in: PubMed

People

Explore

Similar Concepts

Top Journals